U.S. markets close in 2 hours 37 minutes
  • S&P 500

    4,159.58
    -25.89 (-0.62%)
     
  • Dow 30

    34,031.84
    -168.83 (-0.49%)
     
  • Nasdaq

    13,891.58
    -160.76 (-1.14%)
     
  • Russell 2000

    2,225.83
    -36.84 (-1.63%)
     
  • Crude Oil

    63.39
    +0.26 (+0.41%)
     
  • Gold

    1,771.50
    -8.70 (-0.49%)
     
  • Silver

    25.82
    -0.29 (-1.11%)
     
  • EUR/USD

    1.2042
    +0.0062 (+0.52%)
     
  • 10-Yr Bond

    1.5920
    +0.0190 (+1.21%)
     
  • GBP/USD

    1.3990
    +0.0150 (+1.08%)
     
  • USD/JPY

    108.0890
    -0.6940 (-0.64%)
     
  • BTC-USD

    55,304.85
    -567.28 (-1.02%)
     
  • CMC Crypto 200

    1,246.45
    -52.51 (-4.04%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Quanterix to Present at the 10th Annual SVB Leerink Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be presenting at the 10th Annual SVB Leerink Global Healthcare Conference, being held virtually from February 22 – 26, 2021. Hrusovsky’s presentation will take place on Friday, February 26, at 9:20 a.m. EST.

Attendees can access the public webcast at https://wsw.com/webcast/svbleerink47/qtrx/2717696 or by visiting the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com/. Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005830/en/

Contacts

Media Contact:
PAN Communications
Staci Didner, (407) 734-7325
quanterix@pancomm.com

Investor Relations Contact:
Stephen Hrusovsky
(774) 278-0496
shrusovsky@quanterix.com